C12N 9/6491
Matrix metalloproteases [mmp's]
Official title: {Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)}
C12N9/6491 (Matrix metalloproteases [mmp's]) appears on 245 US grants and 334 published applications in this corpus.
Search patents in C12N- Granted patents
- 245
- Published applications
- 334
- Assignees
- 153
- Inventors
- 554
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 7 | 0 |
| 1999 | 2 | 0 |
| 2000 | 7 | 0 |
| 2001 | 13 | 1 |
| 2002 | 8 | 12 |
| 2003 | 7 | 15 |
| 2004 | 3 | 18 |
| 2005 | 2 | 13 |
| 2006 | 7 | 8 |
| 2007 | 9 | 6 |
| 2008 | 4 | 8 |
| 2009 | 3 | 7 |
| 2010 | 2 | 7 |
| 2011 | 7 | 10 |
| 2012 | 2 | 7 |
| 2013 | 3 | 11 |
| 2014 | 8 | 8 |
| 2015 | 5 | 3 |
| 2016 | 2 | 19 |
| 2017 | 8 | 17 |
| 2018 | 26 | 25 |
| 2019 | 20 | 20 |
| 2020 | 9 | 22 |
| 2021 | 12 | 23 |
| 2022 | 17 | 21 |
| 2023 | 7 | 20 |
| 2024 | 15 | 9 |
| 2025 | 6 | 12 |
| 2026 | 5 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Protease-cleavable substrates and methods of use thereof5 May 2026US 12,617,856 B2CytomX Therapeutics, Inc.
- Blends containing proteases5 May 2026US 12,618,058 B2Roche Diagnostics Operations, Inc.
- Protease-cleavable substrates and methods of use thereof31 Mar 2026US 12,589,164 B1CytomX Therapeutics, Inc.
- Protease-cleavable substrates and methods of use thereof17 Feb 2026US 12,551,571 B2CytomX Therapeutics, Inc.
- Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase6 Jan 2026US 12,516,310 B2Connext Limited
- Brevibacillus laterosporus and method for extracting collagen/collagen peptides using brevibacillus laterosporus10 Sep 2026US 2026/0265344 A1Barel(Guangzhou)New Material Technology Co.,Ltd
- Gene editing for intervertebral, intra- and peridiscal therapy and associated spinal disorders16 Jul 2026US 2026/0199521 A1Orthobio Therapeutics, Inc.
- Fusions with proteases and uses thereof2 Jul 2026US 2026/0183373 A1Genentech, Inc.
- Protease-cleavable substrates and methods of use thereof2 Jul 2026US 2026/0183415 A1CytomX Therapeutics, Inc.
- Enhanced macrophages2 Apr 2026US 2026/0091058 A1Resolution Therapeutics Limited
Most cited
By later US patents
- Modified peptides as therapeutic agents359US 6,660,843 B1Amgen Inc. · 2003
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Compositions of chondrocytes, preparation and utilization145US 6,365,405 B1Universite Pierre et Marie Curie (Paris IV) · 2002
- Immunotherapy against several tumors, such as lung cancer, including NSCLC131US 9,943,579 B2Immatics Biotechnologies GmbH · 2018
- Methods for designing agents that interact with MMP-1395US 6,934,639 B1Wyeth · 2005